# Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure

> **NCT03128528** · PHASE2 · COMPLETED · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 84 (actual)

## Conditions studied

- Chronic Heart Failure

## Interventions

- **DRUG:** Empagliflozin 10mg
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03128528
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2020-01-31
- **Final completion:** 2020-04-30
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2020-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03128528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03128528, "Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03128528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*